+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07654855

Characterizing Long-Term Safety and Use of Eplontersen in Transthyretin Amyloidosis Patients with Liver Transplant or Severe Hepatic Impairment

Led by AstraZeneca · Updated on 2026-09-14

320

Participants Needed

6

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting an observational cohort study to understand how eplontersen is used in patients with transthyretin amyloidosis ATTR, including those who have had a liver transplant or have severe liver impairment. The study aims to fill gaps in knowledge about these patient groups and to assess the long-term safety of eplontersen among all new users. It includes adults aged 18 and older with a confirmed ATTR diagnosis. The study collects data from participants who started eplontersen treatment within one year before joining the study, as well as comparative data from patients who started other ATTR treatments but have not used eplontersen. Data collection will begin in the third quarter of 2026 and continue until the first quarter of 2032, with annual interim reports and a final report in early 2033. There is no active treatment given as part of this study since it is observational. Participants provide data through the study observation period, which monitors demographic and clinical characteristics, liver transplant history, and severe hepatic impairment prevalence. Researchers track long-term safety by recording new clinical events, abnormal lab results, and serious adverse events. Safety events are monitored closely and analyzed over specific time intervals throughout the study duration, which lasts about five and a half years.

CONDITIONS

Brief Title

Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here